Active Stocks
Thu Mar 28 2024 15:59:33
  1. Tata Steel share price
  2. 155.90 2.00%
  1. ICICI Bank share price
  2. 1,095.75 1.08%
  1. HDFC Bank share price
  2. 1,448.20 0.52%
  1. ITC share price
  2. 428.55 0.13%
  1. Power Grid Corporation Of India share price
  2. 277.05 2.21%
Business News/ Companies / News/  Pfizer acquires Array Biopharma, valued at $11.4 billion
BackBack

Pfizer acquires Array Biopharma, valued at $11.4 billion

Pfizer says it offered $48 per share in cash for Array, putting an $11.4 billion value on the company
  • The transaction shows how big pharmaceutical companies are looking to biotech acquisitions for growth, often buying them for astronomical sums
  • Photo: ReutersPremium
    Photo: Reuters

    NEW YORK : US pharmaceutical giant Pfizer on Monday announced the acquisition of Array BioPharma, a biotechnology firm that specializes in cancer drugs, the latest in a long list of biotech mergers in recent years.

    In a statement, Pfizer said it offered $48 per share in cash for Array, putting an $11.4 billion value on the company.

    "The board of directors of both companies have approved the merger," Pfizer said.

    The proposed acquisition "sets the stage to create a potentially industry-leading franchise for colorectal cancer alongside Pfizer's existing expertise in breast and prostate cancers," Pfizer CEO Albert Bourla said.

    Array's portfolio includes two drugs, Braftovi (encorafenib) and Mektovi (binimetinib), that when combined are effective in treating BRAF-mutant melanoma.

    The combination of the two drugs was authorized in September by the European Commission, several months after the US Federal Drug Administration gave its approval.

    Besides melanomas, BRAF mutations occur in up to 15 percent of colorectal cancers, Pfizer said.

    The transaction shows how big pharmaceutical companies are looking to biotech acquisitions for growth, often buying them for astronomical sums.

    In early January, Bristol-Myers-Squibb acquired Celgene in a $74 billion mega merger.

    Last year, Sanofi scooped up Bioverativ, which specializes in hemophilia treatments, for $11.6 billion and forked out $3.9 billion euros from Ablynx of Belgium.

    Novartis for its part picked up AveXis, which specializes in rare genetic maladies, for $8.7 billion.

    Unlock a world of Benefits! From insightful newsletters to real-time stock tracking, breaking news and a personalized newsfeed – it's all here, just a click away! Login Now!

    Catch all the Corporate news and Updates on Live Mint. Download The Mint News App to get Daily Market Updates & Live Business News.
    More Less
    Published: 17 Jun 2019, 07:34 PM IST
    Next Story footLogo
    Recommended For You
    Switch to the Mint app for fast and personalized news - Get App

    Chat with MintGenie